Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Rated “Hold” by Wall Street Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have been given an average rating of “Hold” by the twenty-two brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $33.65.

Several research analysts have recently issued reports on the company. UBS Group initiated coverage on Ultragenyx Pharmaceutical in a research note on Thursday, October 15th. They issued a “neutral” rating and a $16.00 price objective for the company. Evercore downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price target on the stock. in a report on Thursday, September 3rd. Robert W. Baird downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $40.00 to $16.00 in a report on Thursday, September 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, October 6th. Finally, Guggenheim decreased their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $16.75 on Wednesday. The business has a fifty day moving average of $17.55 and a 200 day moving average of $22.99. Ultragenyx Pharmaceutical has a 1 year low of $12.73 and a 1 year high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.32. The firm had revenue of $214.00 million for the quarter, compared to analysts’ expectations of $183.08 million. The firm’s revenue for the quarter was up 28.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.17) EPS. Equities research analysts anticipate that Ultragenyx Pharmaceutical will post -3.91 EPS for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,066 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $15.27, for a total transaction of $107,897.82. Following the completion of the transaction, the chief financial officer directly owned 89,229 shares in the company, valued at $1,362,526.83. The trade was a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 8,510 shares of company stock valued at $127,561 in the last quarter. 5.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC raised its stake in shares of Ultragenyx Pharmaceutical by 778.4% during the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,440 shares during the last quarter. Sterling Capital Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 102.4% in the third quarter. Sterling Capital Management LLC now owns 2,475 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 1,252 shares during the last quarter. Leonteq Securities AG boosted its stake in shares of Ultragenyx Pharmaceutical by 288.5% in the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 1,333 shares during the last quarter. Versant Capital Management Inc grew its holdings in Ultragenyx Pharmaceutical by 662.9% during the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,001 shares during the period. Finally, EverSource Wealth Advisors LLC grew its holdings in Ultragenyx Pharmaceutical by 573.0% during the first quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 1,845 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.